Bonds 2026 – 2034
Issuer | Fresenius SE & Co. KGaA |
Currency | € |
Issue amount | 500,000,000 |
Value date | July 08, 2026 |
Maturity | July 08, 2034 |
Coupon | 3.750% |
Coupon payment | July 08 |
Rating | BBB / Baa3 / BBB- |
Stock exchange | Luxembourg / Regulated Market |
Denomination | 1,000 |
Clearing agency | Clearstream Luxembourg / Euroclear |
ISIN Code | XS3435670222 |
Bonds 2026 – 2031
Issuer | Fresenius SE & Co. KGaA |
Currency | € |
Issue amount | 500,000,000 |
Value date | July 08, 2026 |
Maturity | July 08, 2031 |
Coupon | 3.375% |
Coupon payment | July 08 |
Rating | BBB / Baa3 / BBB- |
Stock exchange | Luxembourg / Regulated Market |
Denomination | 1.000 |
Clearing agency | Clearstream Luxembourg / Euroclear |
ISIN Code | XS3435668325 |
The information and documents contained on the following pages of this website are for information purposes only. These materials do neither constitute an offer nor an invitation to subscribe to or to purchase securities, nor any investment advice or service, and are not meant to serve as a basis for any kind of obligation, contractual or otherwise. Securities may not be offered or sold in the United States of America (“US”) absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. The securities described on the following pages are not offered for sale in the US or to "US persons" (as defined in Regulation S under the US Securities Act of 1933, as amended).
THE FOLLOWING INFORMATION AND DOCUMENTS ARE NOT DIRECTED AT AND ARE NOT INTENDED FOR USE BY (I) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN THE US, CANADA, JAPAN OR AUSTRALIA OR WHO ARE US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), OR (II) PERSONS IN ANY OTHER JURISDICTION WHERE THE COMMUNICATION OR RECEIPT OF SUCH INFORMATION IS RESTRICTED IN SUCH A WAY THAT PROVIDES THAT SUCH PERSONS SHALL NOT RECEIVE IT. SUCH PERSONS, OR PERSONS ACTING FOR THE BENEFIT OF ANY SUCH PERSONS, ARE NOT PERMITTED TO VISIT THE FOLLOWING PAGES OF THE WEBSITE.
To visit the following parts of this website you must confirm that
(i) you are not a resident of the United States of America, Canada, Japan or Australia or a "US person" (as defined in Regulation S under the US Securities Act of 1933, as amended),
(ii) you are not a person to whom the communication of the information contained on the website is restricted,
(iii) you will not distribute any of the information and documents contained thereon to any such person, and
(iv) you are not acting for the benefit of any such person.
By clicking on the "Accept" button below, you will be deemed to have made this confirmation.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SINGAPORE OR JAPAN.
---
Fresenius SE & Co. KGaA announced the successful issuance of a €1 billion dual-tranche bond offering on July 1, 2026. The bonds are expected to settle on July 8, 2026.
The transaction consists of the following two tranches:
- €500 million of fixed rate notes with a coupon rate of 3.375%, maturing July 8, 2031; and
- €500 million of fixed rate notes with a coupon rate of 3.750%, maturing July 8, 2034.
Fresenius will use the net proceeds of the offering for general corporate purposes, including the refinancing of existing financial liabilities.
The bonds were issued by Fresenius SE & Co. KGaA under the Fresenius Debt Issuance Program. The company has applied to have the bonds admitted to trading on the regulated market of the Luxembourg Stock Exchange.
The bond issuance does not impact Fresenius' full-year 2026 financial guidance, and the transaction fully covers refinancing requirements for the full year 2026 while proactively addressing certain debt maturities in 2027.
Overall, the transaction further strengthens Fresenius’ financial flexibility, limits potential future refinancing risks, and supports the balance sheet. In addition, the Company successfully extends the average maturity of its debt portfolio. Fresenius remains committed to its self-imposed target leverage corridor of 2.5 to 3.0x net debt/EBITDA. Deleveraging and a strong balance sheet are clear priorities within the Company’s stated capital allocation priorities, which are key to delivering the ambitions of #FutureFresenius.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, Singapore or the United States of America (the “United States”) or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada, Japan or Singapore or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada, Japan or Singapore. The offer and sale of the securities referred to herein has not been and will not be registered under the Securities Act or under the applicable securities laws of Australia, Canada, Japan or Singapore. There will be no public offer of the securities in the United States.
This announcement contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Neither Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company nor Fresenius Finance Ireland II Public Limited Company undertake any responsibility to update the forward-looking statements in this announcement.
This announcement is a general information and not a prospectus. It has been prepared on the basis that any offer of securities in any Member State of the European Economic Area ("EEA") will be made pursuant to the prospectus and any supplement thereto prepared by Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company and Fresenius Finance Ireland II Public Limited Company in combination with the relevant final terms relating to such securities or pursuant to an exemption under Regulation (EU) 2017/1129 (the “Prospectus Regulation”) from the requirement to publish a prospectus for offers of securities. Investors should not purchase or subscribe for any securities referred to in this announcement except on the basis of information in the prospectus, as supplemented, in combination with the relevant final terms relating to such securities, to be issued by the company in connection with the offering of such securities. The applicable final terms for such securities, when published, will be available on the website of the Luxembourg Stock Exchange (www.LuxSE.com) together with the prospectus and any supplement thereto. Copies of the prospectus are also available free of charge from Fresenius SE & Co. KGaA at Else-Kröner Strasse 1, 61352 Bad Homburg, Germany.
This announcement is directed at and/or for distribution in the United Kingdom only to (i) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (ii) high net worth entities falling within article 49(2)(a) to (d) of the Order (all such persons are referred to herein as “relevant persons”). This announcement is directed only at relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.
The information and documents contained on the following pages of this website are for information purposes only. These materials do neither constitute an offer nor an invitation to subscribe to or to purchase securities, nor any investment advice or service, and are not meant to serve as a basis for any kind of obligation, contractual or otherwise. Securities may not be offered or sold in the United States of America (“US”) absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. The securities described on the following pages are not offered for sale in the US or to "US persons" (as defined in Regulation S under the US Securities Act of 1933, as amended).
THE FOLLOWING INFORMATION AND DOCUMENTS ARE NOT DIRECTED AT AND ARE NOT INTENDED FOR USE BY (I) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN THE US, CANADA, JAPAN OR AUSTRALIA OR WHO ARE US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), OR (II) PERSONS IN ANY OTHER JURISDICTION WHERE THE COMMUNICATION OR RECEIPT OF SUCH INFORMATION IS RESTRICTED IN SUCH A WAY THAT PROVIDES THAT SUCH PERSONS SHALL NOT RECEIVE IT. SUCH PERSONS, OR PERSONS ACTING FOR THE BENEFIT OF ANY SUCH PERSONS, ARE NOT PERMITTED TO VISIT THE FOLLOWING PAGES OF THE WEBSITE.
To visit the following parts of this website you must confirm that
(i) you are not a resident of the United States of America, Canada, Japan or Australia or a "US person" (as defined in Regulation S under the US Securities Act of 1933, as amended),
(ii) you are not a person to whom the communication of the information contained on the website is restricted,
(iii) you will not distribute any of the information and documents contained thereon to any such person, and
(iv) you are not acting for the benefit of any such person.
By clicking on the "Accept" button below, you will be deemed to have made this confirmation.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SINGAPORE OR JAPAN.
---
Fresenius SE & Co. KGaA announced the successful issuance of a €1 billion dual-tranche bond offering on July 1, 2026. The bonds are expected to settle on July 8, 2026.
The transaction consists of the following two tranches:
- €500 million of fixed rate notes with a coupon rate of 3.375%, maturing July 8, 2031; and
- €500 million of fixed rate notes with a coupon rate of 3.750%, maturing July 8, 2034.
Fresenius will use the net proceeds of the offering for general corporate purposes, including the refinancing of existing financial liabilities.
The bonds were issued by Fresenius SE & Co. KGaA under the Fresenius Debt Issuance Program. The company has applied to have the bonds admitted to trading on the regulated market of the Luxembourg Stock Exchange.
The bond issuance does not impact Fresenius' full-year 2026 financial guidance, and the transaction fully covers refinancing requirements for the full year 2026 while proactively addressing certain debt maturities in 2027.
Overall, the transaction further strengthens Fresenius’ financial flexibility, limits potential future refinancing risks, and supports the balance sheet. In addition, the Company successfully extends the average maturity of its debt portfolio. Fresenius remains committed to its self-imposed target leverage corridor of 2.5 to 3.0x net debt/EBITDA. Deleveraging and a strong balance sheet are clear priorities within the Company’s stated capital allocation priorities, which are key to delivering the ambitions of #FutureFresenius.
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, Singapore or the United States of America (the “United States”) or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada, Japan or Singapore or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada, Japan or Singapore. The offer and sale of the securities referred to herein has not been and will not be registered under the Securities Act or under the applicable securities laws of Australia, Canada, Japan or Singapore. There will be no public offer of the securities in the United States.
This announcement contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Neither Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company nor Fresenius Finance Ireland II Public Limited Company undertake any responsibility to update the forward-looking statements in this announcement.
This announcement is a general information and not a prospectus. It has been prepared on the basis that any offer of securities in any Member State of the European Economic Area ("EEA") will be made pursuant to the prospectus and any supplement thereto prepared by Fresenius SE & Co. KGaA, Fresenius Finance Ireland Public Limited Company and Fresenius Finance Ireland II Public Limited Company in combination with the relevant final terms relating to such securities or pursuant to an exemption under Regulation (EU) 2017/1129 (the “Prospectus Regulation”) from the requirement to publish a prospectus for offers of securities. Investors should not purchase or subscribe for any securities referred to in this announcement except on the basis of information in the prospectus, as supplemented, in combination with the relevant final terms relating to such securities, to be issued by the company in connection with the offering of such securities. The applicable final terms for such securities, when published, will be available on the website of the Luxembourg Stock Exchange (www.LuxSE.com) together with the prospectus and any supplement thereto. Copies of the prospectus are also available free of charge from Fresenius SE & Co. KGaA at Else-Kröner Strasse 1, 61352 Bad Homburg, Germany.
This announcement is directed at and/or for distribution in the United Kingdom only to (i) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (ii) high net worth entities falling within article 49(2)(a) to (d) of the Order (all such persons are referred to herein as “relevant persons”). This announcement is directed only at relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.
Fresenius is integrated into a diverse network of interest groups. From this exchange, we gain valuable insights that help us to continuously improve the management of material topics and reporting.
Our Approach
We engage with our stakeholders through a variety of channels. The corporate functions at Fresenius primarily focus on stakeholders who are relevant to the Group as a whole. The Operating Companies actively engage with patients, employees, customers, and regulatory authorities, among others.
For the integration of potentially affected stakeholders in our operating activities, we consider, for example, findings from existing due diligence processes and risk assessments in quality, internal employee satisfaction surveys, dialogs with employee representatives and works councils, patient and customer surveys.
➔ Read more in our Sustainability Statement.
Initiatives & Memberships
An important element of our stakeholder dialogs is our active participation in industry and interest groups, as well as our exchange with business partners. Our employees contribute their expertise to national and international bodies, committees, and associations.
We are committed to observing the codes and principles associated with our membership in various associations. In addition, we disclose all contributions made to healthcare professionals in the companies of Fresenius in accordance with the applicable disclosure requirements.
Fresenius has a Sponsored Level 1 American Depositary Receipt (ADR) Program in the United States. The ADRs are traded under the ticker symbol "FSNUY" in the over-the-counter market tier.
ADR information
Structure | Sponsored Level 1 ADR |
Ratio (ADR:ORD) | 4:1 |
Trading Location | OTC |
Ticker Symbol | FSNUY |
CUSIP | 35804M105 |
ISIN | US35804M1053 |
Trading in ADR
ADRs represent ordinary or common shares of a non-U.S. company. Four Fresenius ADRs are the equivalent of one Fresenius ordinary share. They are priced in U.S. dollars and traded in the U.S. over-the-counter (OTC) market. J.P. Morgan Chase Bank N.A is acting as the depositary bank for this ADR program.
Contact details for ADR brokers & institutional investors:
U.S. Tel: +1 212 552 8926
Hong Kong Tel: +852 2800 1857
e-mail: drx_depo@jpmorgan.com
Computershare contacts for ADR registered holders of Fresenius:
Computershare Shareowner Services
Phone (US & Canada – toll free): +1-866-723-8257
Phone (International): +1-781-575-2833
For regular correspondence:
Computershare Shareowner Services
P.O. Box 43304 Providence, RI 0290-3304, USA
Email: web.queries@computershare.com
Website: www.computershare.com/investor or www.computershare.com/us/contact-us
For delivery of stock certificates & overnight mail:
Computershare Trust Company, N.A
150 Royall Street
Canton, MA 02021
Fresenius’ ADR program is administered by J.P. Morgan Chase Bank N.A. As the depositary bank, J.P. Morgan Chase Bank N.A performs the following roles for registered ADR holders as further detailed in the Deposit Agreement:
- Records and maintains the register of ADR holders,
- Is the stock transfer agent,
- Distributes dividends in U.S. dollars,
- Facilitates the voting process and the exercise of the voting rights of ADR holders at any Company General Meeting if permitted by the Company and the Depositary Agreement,
- Issues and cancels Fresenius American Depositary Receipts (ADRs),
- Can distribute Company circulars and General Meetings (including Annual General Meeting) documentation, if applicable.
For those holders who are not registered because their ADRs are held through a ‘Street name’ (nominee account), your nominee will from time to time receive Company documents from J.P. Morgan Chase Bank N.A to distribute to ADR holders. You need to make arrangements with your nominee if you wish to receive such documents and to be able to exercise your vote through the depositary bank at General Meetings (if applicable).
Contact
Director Investor Relations
T: +49 (0) 6172 608-5211
stefanie.drees@fresenius.com
Related Links
Historical ADR prices and interactive chartsAs a global healthcare company, our actions are guided by clear principles, standards, and governance structures. They form the basis for acting responsibly and with integrity across the Group.
Within our Sustainability Framework, the Ethical Foundation defines how we embed ethical behavior in our processes, decisions, and relationships. This includes ensuring compliance, respecting human rights, and maintaining clear standards for responsible and ethical conduct. It also includes our commitment to quality, which is essential to ensuring the safety and reliability of our products and services.
Integrity is the foundation of trust – within our organization and in our interactions with patients, partners, regulators, and society. We aim to foster a culture where ethical behavior and quality are consistently reflected in how we operate.
The Ethical Foundation of our Sustainability Framework encompasses the following focus topics:
For us, quality excellence means a commitment to providing leading product and service quality and safety, driven by continuous improvement and effectiveness. We want to bring healthcare innovations to the people and thus provide value for patients.
Since our operations encompass healthcare services, pharmaceuticals, and medical technology, the quality requirements naturally vary. Our quality management systems are specifically designed to address these diverse needs, meeting both internal standards and external requirements. We ensure this through robust processes and comprehensive training programs across all areas of our business. To track our performance, we use clearly defined quality indicators and targets. These are not only embedded in our daily work but also tied to the variable compensation of our Management Board.
➔ Read more in our Sustainability Statement.
Innovation is key to meeting the needs of our patients – today and in the future. For us, it is a driving force behind improving treatment options, streamlining workflows, and delivering high-quality healthcare solutions. Our integrated approach spans the entire value chain and focuses, among other things, on initiatives that enhance therapies and patient experience through research, telemedicine, and Artificial Intelligence.
The quality of our products, services, and therapies is the basis for optimal medical care.
➔ Read more in our Sustainability Statement.
We are committed to respecting human rights.
Patients, doctors, nursing and administrative staff rely on our products, concepts, and solutions. Around 180,000 employees place their trust in Fresenius as an employer. At the same time, we rely on thousands of people worldwide who work for our suppliers and business partners in our value chain.
Our Human Rights Program is based on internationally recognized standards and frameworks, including the Universal Declaration of Human Rights, the Core Labor Standards of the International Labour Organization, the UN Guiding Principles on Business and Human Rights, and the OECD Due Diligence Guidance for Responsible Business Conduct.
Our commitment to respect human rights is an integral part of our responsibility as a global healthcare company.
➔ Read more on our Human Rights page.
We are committed to high ethical business standards – out of responsibility toward patients, employees, the environment, and society.
We believe in doing the right thing. That means acting not only in line with legal requirements, but also in accordance with industry codes, internal policies, and our values – the Fresenius Principles. Internal and external controls help ensure compliance and safeguard the trust our stakeholders place in us.
No matter the role, our work is grounded in the Fresenius Code of Conduct.
➔ Read more on our Compliance page.
Sustainability Insights
Explore our stories to learn what sustainability looks like in our daily operations:
-
HeSaMeDa: Using data securely for better care
With diagnostic and therapeutic information, test samples from the laboratory, and other treatment data – hospitals are sitting on a wealth of data. Evaluating this data can help to better understand the relationships between therapy procedures and treatment outcomes, identify patterns, and develop innovative treatment methods.
-
Enhancing patient experience: Bridging digital care and energy consumption
Enhancing patient experience is one of Fresenius’ top priorities – and digitalization plays an important role in achieving this. In 2025, Quirónsalud launched a pilot project at a hospital in Southern Spain to connect our digital platform Casiopea with the hospital’s Building Management System.
-
What exactly is … a hospital cluster?
Fresenius Helios has grouped its roughly 80 hospitals in Germany into 21 clusters. The aim is to deliver patient care while further enhancing medical quality and efficiency.
-
Resistant pathogens: Prevention in hospitals and when manufacturing antibiotics
Antibiotics play a key role in modern medicine. They treat bacterial infections and prevent them from spreading. In certain cases, however, their reliability can no longer be relied upon. That’s because antimicrobial resistance – the incidence of resistant pathogens – is spreading worldwide.
As a healthcare company, we operate in a demanding environment where patient safety and hygiene requirements are always a top priority. At the same time, we are committed to reducing the environmental impact of our activities.
Within our Sustainability Framework, the Planet Dimension, we focus on minimizing our environmental footprint, contributing to climate protection, and using natural resources responsibly, including water and materials, and reducing waste. In doing so, we aim to balance environmental responsibility with the requirements of high-quality patient care.
We recognize that a healthy environment is closely linked to human health. By reducing the environmental impact of our operations, we aim to contribute to climate protection and the responsible use of natural resources by focusing on defined areas such as decarbonization and water management within our Sustainability Framework.
The Planet Dimension of our Sustainability Framework encompasses the following focus topics:
We have a clear target: net zero emissions from our own operations and along our value chain by 2050.
Fresenius manufactures medical products and operates healthcare facilities, which inevitably results in energy consumption and associated greenhouse gas emissions. In production, for example, the machines and containers have to be sterilized, and in our hospitals a wide variety of technical systems are in constant operation. This presents us with special challenges: On the one hand, we want to reduce our energy demand as far as possible and on the other hand, we must always guarantee the safety of patients in our facilities and ensure a stable supply of energy in our production.
We want to live up to our responsibilities and help achieve the goal of the Paris Climate Agreement: Our climate targets aim to limit global warming to 1.5 °C. All our climate protection activities contribute to our long-term objective of attaining net zero by 2050: This requires a company to reduce its avoidable greenhouse gas emissions, while unavoidable emissions must be offset by removing an equivalent amount from the atmosphere and storing it for the long term.
Within our own operations, we are committed to reducing our Scope 1 and Scope 2 emissions by 50% by 2030.
Scope 1 and Scope 2 target pathway to 2030
The decarbonization of our value chain is a decisive factor on our long-term path to net zero. Scope 3 emissions include greenhouse gases that are released indirectly in our upstream and downstream value chains – such as from purchased raw materials or at the end of the life of sold products.
Climate change is also a health issue. Rising temperatures, more frequent heatwaves and changing weather patterns directly affect people's health, particularly vulnerable groups such as the elderly, chronically ill, and children. Heat stress can lead to circulatory problems, dehydration and an increased risk of death. At the same time, climate change contributes to the spread of infectious diseases, for example by introducing new vectors such as mosquitoes or contaminating water sources. As a healthcare company, we therefore consider it our responsibility to not only react to the effects of climate change, but also actively contribute to mitigating it. After all, climate protection is health protection.
We place particular emphasis on preserving water quality. In water-stressed areas, we are especially committed to reducing our water withdrawal.
Water is one of our most valuable resources. As a healthcare company, we are dependent on water: We need drinking water of the highest quality to ensure safe patient care. It is crucial for hygiene and well-being. We also use water in the production of our pharmaceutical products – as process water as well as product component. The quality requirements for this water are even higher than those for drinking water.
It is our ambition to avoid or minimize any negative impact on the environment that may arise from our direct business operations or from downstream activities. This also includes avoiding unnecessarily polluting the sources from which we obtain water or into which we discharge our wastewater.
At Fresenius, we focus on reducing our waste and embedding circular principles into product design and packaging solutions.
We are committed to conserving natural resources wherever possible. In doing so, we always have to strike a balance between resource efficiency and hygiene requirements. Disposable items are often used in clinics for hygienic reasons. Our options for saving resources are limited here. There are also strict regulations for pharmaceutical packaging. Our most important levers for conserving resources are therefore developing durable and resource-saving products, reusing resources wherever possible, and disposing of waste safely and systematically.
Sustainability Insights
Explore our stories to learn what sustainability looks like in our daily operations:
-
Resistant pathogens: Prevention in hospitals and when manufacturing antibiotics
Antibiotics play a key role in modern medicine. They treat bacterial infections and prevent them from spreading. In certain cases, however, their reliability can no longer be relied upon. That’s because antimicrobial resistance – the incidence of resistant pathogens – is spreading worldwide.
-
What do anesthetic gases have to do with the climate?
Anesthetic gases are an indispensable part of modern medicine. At the same time, they represent one of the largest direct sources of emissions in hospital operations, with their global warming potential exceeding that of CO2 many times over. Thanks to modern medical technology, special systems can be used to capture anesthetic gases instead of releasing them unimpeded into the atmosphere.
-
Enhancing patient experience: Bridging digital care and energy consumption
Enhancing patient experience is one of Fresenius’ top priorities – and digitalization plays an important role in achieving this. In 2025, Quirónsalud launched a pilot project at a hospital in Southern Spain to connect our digital platform Casiopea with the hospital’s Building Management System.